Company Search
CEO Interview
Drive With Dynacor Video Series
TSX_DNG on 2012-05-17 10:38Dynacor has released a new video series called the "Drive With Dynacor". http://youtu.be/seFbg2CXt6U
NAI Blog
My Top Junior Oil Stock in the Permian Basin “Tight” Oil Play Keith Schaefer on 2012-04-26 07:40:54Part 2: The Permian Basin – Cline Shale Resource Play
Company News - Company Data
Transition Therapeutics Announces Third Quarter Fiscal 2012 Financial Results
Posted 2012-05-08 07:02NAI Editing
a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2012.Transition Therapeutics Appoints New Chief Financial Officer
Posted 2011-12-12 00:51NAI Editing
today announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial Officer of Transition. Ms.Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401
Posted 2011-12-12 00:50NAI Editing
announced today the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug candidate, TT-401.Transition Therapeutics Announces US$5 Million Private Placement
Posted 2011-11-21 01:45NAI Editing
today announced that it has entered into agreements to issue 3,703,703 common shares at a price of US$1.35 per share for gross proceeds of approximately US$5 million, by way of a non-brokered private Transition Therapeutics Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
Posted 2011-09-26 23:55NAI Editing
announced that Phase 2 clinical study data of ELND005 in mild to moderate Alzheimer's disease has been published today in the peer-reviewed journal, Neurology.Clinical Study of TT-223 in Combination With a GLP-1 Analogue Does Not Meet Study Efficacy Endpoints
Posted 2010-09-17 08:57NAI500 Admin
announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints.Transition Therapeutics Announces Initiation of a Phase I Clinical Study of TT-301
Posted 2010-06-30 09:01NAI500 Admin
announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study.
Posted 2012-05-08 07:02
NAI Editinga product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2012.Transition Therapeutics Appoints New Chief Financial Officer
Posted 2011-12-12 00:51
NAI Editingtoday announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial Officer of Transition. Ms.Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401
Posted 2011-12-12 00:50
NAI Editingannounced today the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug candidate, TT-401.Transition Therapeutics Announces US$5 Million Private Placement
Posted 2011-11-21 01:45
NAI Editingtoday announced that it has entered into agreements to issue 3,703,703 common shares at a price of US$1.35 per share for gross proceeds of approximately US$5 million, by way of a non-brokered private Transition Therapeutics Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
Posted 2011-09-26 23:55
NAI Editingannounced that Phase 2 clinical study data of ELND005 in mild to moderate Alzheimer's disease has been published today in the peer-reviewed journal, Neurology.Clinical Study of TT-223 in Combination With a GLP-1 Analogue Does Not Meet Study Efficacy Endpoints
Posted 2010-09-17 08:57
NAI500 Adminannounced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints.Transition Therapeutics Announces Initiation of a Phase I Clinical Study of TT-301
Posted 2010-06-30 09:01
NAI500 Adminannounced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study.